Nyxol in combination with low-dose pilocarpine successfully met primary and key secondary endpoints in a phase 2 trial evaluating its safety and efficacy for presbyopia, according to a press release from Ocuphire Pharma.
The randomized, double-masked, placebo-controlled VEGA-1 trial was a four-armed study investigating improvement in photopic binocular near vision after treatment with Nyxol (0.75% phentolamine ophthalmic solution) combined with low-dose pilocarpine.
The study enrolled 150 patients across 17 centers in the United States.
Sixty-one percent of subjects in the Nyxol and low-dose